These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33580780)

  • 1. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
    Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
    Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.
    Saeed A; Feofanova EV; Yu B; Sun W; Virani SS; Nambi V; Coresh J; Guild CS; Boerwinkle E; Ballantyne CM; Hoogeveen RC
    J Am Coll Cardiol; 2018 Jul; 72(2):156-169. PubMed ID: 29976289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Chan DC; Watts GF
    Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
    Mohamed F; Mansfield BS; Raal FJ
    Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.
    Cao YX; Zhang HW; Jin JL; Liu HH; Zhang Y; Xu RX; Gao Y; Guo YL; Zhu CG; Hua Q; Li YF; Santos RD; Wu NQ; Li JJ
    J Lipid Res; 2020 Sep; 61(9):1254-1262. PubMed ID: 32641433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
    Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
    Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Reeskamp LF; Tromp TR; Stroes ESG
    Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
    Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
    Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triglyceride-rich lipoprotein, remnant cholesterol, and apolipoproteins CII, CIII, and E in patients with schizophrenia.
    Wang J; Kockx M; Bolek M; Lambert T; Sullivan D; Chow V; Kritharides L
    J Lipid Res; 2024 Jul; 65(7):100577. PubMed ID: 38879166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk.
    Gobeil É; Bourgault J; Mitchell PL; Houessou U; Gagnon E; Girard A; Paulin A; Manikpurage HD; Côté V; Couture C; Marceau S; Bossé Y; Thériault S; Mathieu P; Vohl MC; Tchernof A; Arsenault BJ
    Eur Heart J; 2024 Mar; 45(9):707-721. PubMed ID: 38243829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.
    Hernandez P; Passi N; Modarressi T; Kulkarni V; Soni M; Burke F; Bajaj A; Soffer D
    Curr Atheroscler Rep; 2021 Sep; 23(11):72. PubMed ID: 34515873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
    Hussain A; Ballantyne CM; Saeed A; Virani SS
    Curr Atheroscler Rep; 2020 Jun; 22(7):25. PubMed ID: 32494924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
    Kim JY; Kim NH
    J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
    Ward NC; Chan DC; Watts GF
    BioDrugs; 2022 Mar; 36(2):121-135. PubMed ID: 35286660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
    Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
    Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
    Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
    Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia.
    Nurmohamed NS; Dallinga-Thie GM; Stroes ESG
    Expert Rev Cardiovasc Ther; 2020 Jun; 18(6):355-361. PubMed ID: 32511037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial.
    Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
    Eur J Prev Cardiol; 2024 Aug; 31(10):1216-1223. PubMed ID: 38484368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.